TNF-related apoptosis-inducing ligand or Apo2L (TRAIL) is a promising tool for cancer therapy, owing to its ability to eradicate tumor cells while sparing normal cells. 1 TRAIL is a type II transmembrane protein, whose binding to its agonistic receptors, namely TRAIL-R1 (DR4) and TRAIL-R2 (DR5, TRICK2 or KILLER), triggers apoptosis in a p53-independent manner. Engagement of TRAIL agonistic receptors induces the formation of a molecular platform called the DISC (death-inducing signaling complex) within minutes, through homotypic interactions. 2 This platform includes the adapter protein FADD and caspase-8, an initiator caspase that is activated and subsequently released from the DISC to the cytosol for dismantling of the cells. The amount of caspase-8 generated within the DISC in type I cells is sufficient to trigger apoptosis through the direct activation of the effector caspase-3. Type II cells require the engagement of a mitochondrial amplification loop, which is activated by caspase-8-dependent cleavage of Bid, a BH3-only protein that targets the intrinsic pathway through Bax and Bak, allowing the formation of the apoptosome. However, enforced aggregation of TRAIL agonistic receptors in these cells enhances caspase-8 activation at the DISC level and overcomes mitochondrial checkpoints. 3 Likewise, enhanced caspase-8 recruitment and activation at the TRAIL DISC by chemotherapeutic drugs has been associated with the restoration of TRAIL sensitivity in hepatocellular and colon carcinomas. 4, 5 Cellular resistance to TRAIL-induced cell death arises from a large variety of events, ranging from defects in DISC formation, or inhibition of more distal events, including mitochondrial block. 6, 7 TRAIL-induced cell death can be specifically inhibited by two membrane-bound antagonistic receptors, TRAIL-R3 (DcR1, LIT or TRID) or TRAIL-R4 (DcR2 or TRUNDD). 2 These receptors have been shown to be expressed and to prevent TRAIL-induced cell death in various human primary tumor cells, including lymphomas, lung, breast and prostate carcinomas, [8] [9] [10] but the inhibitory potential of this receptor still remains controversial. 11 Although TRAIL-R3 is a GPI-anchored receptor that sequesters TRAIL into lipid rafts, TRAIL-R4 interacts with TRAIL-R2 within the DISC, and impairs caspase-8 processing, 12 thus, inhibiting TRAILinduced apoptosis. 13, 14 The efficacy of recombinant hAPO2L/TRAIL in association with chemotherapy is evaluated in ongoing clinical trials. 1 It remains unknown whether TRAIL-R4 expression may compromise the efficacy of TRAIL.
We demonstrate here that TRAIL-R4 efficiently inhibits TRAIL, and that chemotherapeutic drugs can overcome this resistance. Restoration of apoptosis primarily occurs at the membrane level, irrespective of the mitochondria, through enhanced caspase-8 recruitment and activation at the TRAIL DISC. TRAIL-R4 expression also impairs TRAIL-induced tumor regression in vivo, but sequential treatments associating CDDP and TRAIL prevent tumor growth in nude mice. Altogether, our results demonstrate that TRAIL-R4 is a negative regulator of TRAIL, whose inhibitory function can be overcome by chemotherapy.
Results
TRAIL and chemotherapeutic drugs synergistically induce apoptosis in TRAIL-R4-expressing cells. We have demonstrated previously that, ectopic expression of TRAIL-R4 impairs TRAIL-induced cell death through the formation of a heteromeric complex with TRAIL-R2, leading to the inhibition of caspase-8 activation within the TRAIL DISC. 12 Owing to the ability of TRAIL-R4 to inhibit TRAILinduced cell death, we evaluated whether its expression may compromise combination therapies associating TRAIL with conventional chemotherapeutic drugs. To test this hypothesis, TRAIL-R4 was ectopically expressed using retroviruses in three TRAIL-sensitive tumoral cell lines, HeLa, Jurkat and SW480. Cell surface expression was assessed by flow cytometry (Figure 1a and b). TRAIL-R4 inhibited TRAIL-induced apoptosis in these cells (Figure 1c and d). Strikingly, TRAIL-R4 also inhibited death induced by chemotherapeutic drugs in some cell lines. Pre-treatment with pharmacological concentrations of CDDP, VP16 for 3 h or 5FU for 72 h, however, restored TRAIL sensitivity in these cells (Figure 1c and d) . Similar results were obtained in the B-lymphoma cell line VAL, in which the cells are poorly sensitive to TRAIL-induced cell death (Figure 1e ). VAL cells endogenously express TRAIL-R4 at the cell surface and high levels of Bcl-2, because of the t(14;18) chromosomal translocation (Figure 1f and g ). Cells sensitivity to TRAIL-induced cell death was restored in VAL cells after pre-treatment with CDDP, VP16, or 5FU (Figure 1e ). siRNA-mediated downregulation of TRAIL-R4 or Bcl-2 expression in VAL cells also restored sensitivity to TRAIL (Figure 1f and g ), demonstrating that both TRAIL-R4 and Bcl-2 are functional in these cells.
Sequential chemotherapy and TRAIL treatments restore caspase activation. Chemotherapeutic drugs enhanced caspase activation upon TRAIL stimulation (Figure 2a ) without changing TRAIL receptor expression (Supplementary Figure S1 ). In HeLa control cells, TRAIL alone triggered the activation of caspase-8, caspase-9 and caspase-3, and induced Bid and PARP cleavage, as demonstrated by the disappearance of their proform or the appearance of cleaved fragments (Figure 2a ). However, in HeLa cells expressing TRAIL-R4 (H-TRAIL-R4 cells), TRAIL induced only a modest cleavage of caspase-8 and caspase-9, resulting in the poor activation of caspase-3 ( Figure 2a ). Pre-treatment of these cells with CDDP, VP16, or 5FU restored caspase-3 activation upon TRAIL stimulation, as demonstrated by the appearance of the caspase-3 p17 fragment and an increase in PARP cleavage (Figure 2a) . Restoration of caspase-3 activation by chemotherapeutic drugs in HeLa-TRAIL-R4 cells was associated with partial activation of both caspase-8 and caspase-9 ( Figure 2a) .
Activation of the mitochondrial intrinsic pathway is not required to restore sensitivity to TRAIL in response to chemotherapy. As most chemotherapeutic drugs engage the mitochondrial pathway to trigger apoptosis, we next analyzed its contribution with regard to chemotherapymediated sensitization to TRAIL-induced cell death. TRAIL stimulation in control HeLa cells triggered the activation of the intrinsic pathway, as evidenced by the disappearance of Bid (Figure 2a ), the release of cytochrome c, Smac/DIABLO and omi to the cytosol (Figure 2b) , and by the activation of Bax (Figure 2d and e). Release of cytochrome c, Smac/ DIABLO and omi were much weaker in H-TRAIL-R4 cells as compared with control cells (Figure 2c ), however, chemotherapy combined with TRAIL nearly completely restored Bax activation in these cells (Figure 2d and e). Overexpression of Bcl-2 or Bcl-xL in H-TRAIL-R4 failed to protect cells from TRAIL-induced apoptosis after chemotherapy (Figure 3a and b) . These results are consistent with the demonstration that chemotherapeutic drugs can restore TRAIL sensitivity in VAL cells, despite large amounts of Bcl-2 expression (Figure 1f) . To determine the role of Bax in drug-mediated sensitization to TRAILinduced cell death, we performed the same experiments in the Bax-deficient or parental WT HCT116 cells engineered to express TRAIL-R4 (Figure 3c ). TRAIL-mediated apoptosis in HCT116 cells was shown to rely on Bax but not Bak activation. 15 According to these findings, TRAIL alone, or simultaneous combinations of TRAIL and 5FU, failed to induce apoptosis in Bax-deficient cells (Figure 3d and Figure 1 Chemotherapeutic drugs restore TRAIL-induced cell death in TRAIL-R4-expressing cells. (a) and (b), HeLa, Jurkat or SW480 cancer cell lines were infected with empty vector (H-Ctl, J-Ctl or SW-Ctl) or with a vector encoding TRAIL-R4 (H-TRAIL-R4, J-TRAIL-R4 or SW-TRAIL-R4). Expression of TRAIL receptors was analyzed by flow cytometry (gray line) against an isotype control (filled curve). (c) and (d), control cells or TRAIL-R4-expressing cells were stimulated with His-TRAIL (500 ng/ml, 6 h), Cisplatin (CDDP, 20 mM, 3 h), etoposide (VP16, 10 mM, 3 h) or 5-fluorouracil (5FU, 1 mg/ml, 72 h). Apoptosis was evaluated after 6 h (TRAIL), 48 h (CDDP or VP16) or 72 h (5FU) by Hoechst staining in HeLa (white), Jurkat (gray) or SW480 (black). Sequential stimulation with chemotherapeutic drugs and TRAIL was performed as follows. Cells were pre-treated with CDDP or VP16 for 3 h, in serum-free medium, then washed and allowed to recover at 37 1C in complete medium for 48 h before stimulation with His-TRAIL (500 ng/ml) for an additional 6 h. Alternatively, cells were stimulated for 72 h with 5FU, then His-TRAIL for 6 h. (e) VAL cell sensitivity to His-TRAIL, chemotherapy or sequential treatments was analyzed as described above. (f) Deregulation of TRAIL-R4 expression in VAL cells using three different siRNAs (scramble siRNA, Src; TRAIL-R4 siRNA, #1, #2 and #3) as analyzed by Facs for TRAIL-R4 expression using an anti-TRAIL-R4 antibody (gray line) or a control isotype (filled curved). The effect of TRAIL-R4 downregulation was assessed by Hoechst staining 6 h after His-TRAIL treatment (500 ng/ml), scramble (white) and TRAIL-R4 siRNA (#1 gray; #2 dashed and #3 black). Sensitization to TRAIL-induced cell death by 5FU has previously been described to involve the deregulation of c-FLIP. 4, 16 We, therefore, analyzed c-FLIP expression after (Figure 3f ), indicating that the mere upregulation of c-FLIP is probably sufficient to impair the synergy irrespective of the mitochondria. In agreement with this finding, the caspase-9 inhibitor z-LEHD-fmk failed to protect TRAIL-R4-expressing cells from TRAIL-induced cell death after chemotherapy, while the pan-caspase inhibitor z-VAD-fmk completely abrogated the synergy (Supplementary Figure S3 ).
Chemotherapeutic drugs enhance caspase-8 recruitment and activation within the TRAIL DISC. To determine the contribution of TRAIL DISC formation and caspase-8 activation in the synergy, c-FLIP was coexpressed in H-TRAIL-R4 cells and cells were stimulated with TRAIL after chemotherapy. Like TRAIL-R4, expression of c-FLIP (Figure 3g ) reduced cell sensitivity to TRAIL, but alone failed to block apoptosis induced by TRAIL upon chemotherapy (Figure 3h ). However, combined expression of TRAIL-R4 and c-FLIP severely impaired TRAIL-induced apoptosis by chemotherapeutic drugs, indicating that activation of caspase-8 per se has a prominent role in the synergy (Figure 3h ). In agreement with these findings, DISC analysis in cells subjected to chemotherapy and TRAIL treatments revealed that chemotherapeutic drugs enhanced caspase-8 recruitment and activation within the TRAIL DISC in HeLa control cells (Figure 4a ) but, probably more importantly, also in HeLa expressing TRAIL-R4 (Figure 4b ) and VAL cells (Figure 4c ), which express TRAIL-R4 endogenously. Altogether, these results clearly demonstrate that TRAIL-R4 inhibits TRAIL-induced cell death, and that chemotherapy can restore tumor cell sensitivity to apoptosis, mainly through the restoration of caspase-8 recruitment and activation within the DISC.
TRAIL-R4 inhibits TRAIL-induced cell death but not chemotherapy-induced sensitization to TRAIL in vivo. Ability of TRAIL-R4 to prevent TRAIL-induced tumor regression, combined or not with chemotherapy, was next evaluated in nude mice using xenografts of HCT116 cells expressing TRAIL-R4. Mice were implanted, in both flanks, with HCT116-Ctl cells (right flank) and HCT116-TRAIL-R4 (left flank). When the tumor volume reached 20 mm 3 , mice were treated with phosphate-buffered saline (PBS), CDDP, recombinant TRAIL or treated sequentially with CDDP and TRAIL as described in the Materials and Methods section. Compared with PBS-treated mice, HCT116-Ctl tumor growth was inhibited in mice receiving injections of TRAIL, CDDP and by the combined treatment (Figure 5a ). However, TRAIL, and to a lesser extent CDDP, failed to induce tumor regression in TRAIL-R4-expressing cells (Figure 5b ), but combined treatments induced a marked inhibition of the tumor growth of HCT116 cells expressing TRAIL-R4 (Figure 5b) , with statistically significant P-values o0.001 as compared with PBS-treated mice. These results demonstrate that TRAIL-R4 efficiently inhibits TRAIL-induced cell death not only in vitro, but also in vivo. However, chemotherapeutic drugs, including CDDP, can overcome TRAIL-R4 mediated resistance, highlighting the potential therapeutic value of these combined therapies for cancer.
Discussion
TRAIL-based combinatorial therapies are emerging paradigms for cancer treatment as synergistic activation of TRAIL-induced apoptosis by chemotherapeutic drugs generally affords to overcome tumor cell resistance, whereas monotherapies are most of the time poorly successful. Preclinical studies and clinical trials are giving promising results, supporting the potential of these combining approaches. 17, 18 Cell surface expression of TRAIL agonistic receptors is the first requirement in order to trigger the TRAIL apoptotic machinery but, to date, the expression of TRAIL receptors in primary tumors remains poorly studied and the anti-apoptotic function of TRAIL-R4 remains controversial. It was found, however, in a few studies that primary lymphomas could express functional TRAIL antagonistic receptors at the cell surface. 10 In solid tumors, analysis of TRAIL receptor expression was often performed by immunohistochemistry, and although this method does not provide the information whether the receptors are expressed at the cell surface, these studies indicate that the extent of expression of the antagonistic receptors TRAIL-R3 and TRAIL-R4 is probably underestimated. 9, [19] [20] [21] Engagement of apoptosis upon TRAIL stimulation in a given tissue type, primary tumor or cell line, relies on the contribution of multiple players, including proapoptotic and prosurvival factors, which ultimately determine cell fate. It has recently been demonstrated that naturally occurring differences in the levels or states of proteins regulating TRAIL signaling are the primary causes of cell-to-cell variability. 22 The large variety of cellular changes in protein levels or status induced by chemotherapeutic drugs may explain why these drugs, restore TRAIL sensitivity in resistant cells, albeit targeting different signaling pathways. Sensitization to TRAIL by chemotherapeutic drugs, has been attributed to multiple molecular mechanisms including the upregulation of TRAIL-R2, 23 activation of the mitochondrial pathway 24, 25 inhibition of c-FLIP expression 26 or enhanced caspase-8 recruitment to the TRAIL DISC. 4, 5 We demonstrate here that chemotherapy overcomes TRAIL resistance induced by TRAIL-R4 at the level of the DISC, and provide strong evidence that the mitochondrial pathway is dispensable for the restoration of TRAIL sensitivity by chemotherapeutic drugs (Figure 6 ). Chemotherapeutic drugs afforded sensitization to TRAIL of aggressive B-cell follicular lymphomas such as VAL cells, despite endogenous expression of functional TRAIL-R4 and Bcl-2. Likewise, these compounds restored TRAIL sensitivity of epithelial-derived tumor cell lines harboring either a deficiency for Bax expression, or engineered to express Bcl-2 or Bcl-x L , irrespective of TRAIL-R4 expression levels. Bax deficiency however, may be detrimental to some chemotherapeutic drugs in cells that express TRAIL-R4 and low but significant levels of c-FLIP. Accordingly, restoration of TRAIL sensitivity in HCT116 Bax-deficient cells expressing TRAIL-R4 was only observed with 5FU, but not CDDP or VP16 because of their ability to induce c-FLIP expression. These results could explain some discrepancies regarding the lack of correlation regarding TRAIL-R4 expression and cell sensitivity to TRAILinduced cell death. In particular, c-FLIP expression levels have scarcely been taken into consideration in these studies.
Our results demonstrate that TRAIL-R4 can inhibit TRAILinduced cell death both in vitro and in vivo, and cooperate with c-FLIP to inhibit chemotherapy-mediated sensitization to TRAIL-induced apoptosis ( Figure 6 ). These findings not only have important implications for the understanding of the molecular mechanisms involved in the regulation of TRAIL signaling, but also for therapeutic approaches aiming at utilizing recombinant TRAIL to cure patients suffering from cancer.
The physiological function and relevance of TRAIL-R4 is still unclear. Our study is probably the first demonstration that TRAIL-R4 can confer TRAIL resistance in vivo, as we demonstrate that ectopic expression of this receptor in the colon carcinoma cell line HCT116 efficiently impairs TRAILinduced tumor killing in nude mice. At the physiological level, TRAIL-R4 could protect cells selectively from TRAIL-induced cell death. Noteworthy, it has been demonstrated that NK and CD8 þ T cells are induced to express TRAIL, TRAIL-R2, TRAIL-R4 and c-FLIP upon activation. 27 Despite high expression levels of TRAIL, these cells are resistant to TRAIL, but selective inhibition of c-FLIP expression induced TRAIL sensitivity. 27 It should be noted, however, that selective TRAIL-R4 downregulation was not assessed in this study, therefore, it is conceivable that TRAIL-R4 may also have a role in protecting these cells from TRAIL-induced cell death. Although the function of TRAIL-R4 remains to be determined in a physiological context, our results indicate that this receptor in pathological conditions, such as overexpression in primary tumor cells, could represent a problem in oncology. Our results clearly support the inhibitory potential of TRAIL-R4 and, in agreement with previous studies, 4,5 sustain the demonstration that chemotherapy sensitize tumor cells to TRAIL mainly through the regulation of caspase-8 activation at the DISC level.
The molecular mechanisms leading to the restoration of caspase-8 recruitment and enhancement of caspase-8 activation within the TRAIL DISC after chemotherapy remains an open question. Some reports indicate that chemotherapeutic drugs could enhance TRAIL receptor clustering at the cell surface, through ceramide production and receptor partitioning into lipid rafts. 28, 29 Work is currently in progress to address this question in our laboratory. Figure 3 The mitochondrial pathway is dispensable for the synergy in TRAIL-R4 expressing HeLa cells. (a) H-TRAIL-R4 cells were infected using the pBabe-blasticidin retroviral vector encoding EGFP or Bcl-2. The expression of the different transgenes was checked by western blot using an anti-Bcl-2 or anti-GFP antibody. Hsc70 was used as a loading control. Molecular size markers are shown on the right in kDa. TRAIL-R4 HeLa cells overexpressing EGFP (EGFP, in white) or Bcl-2 (Bcl-2, in black) were pre-treated with the chemotherapeutic drugs as described in Figure 1 and sequentially treated with His-TRAIL (500 ng/ml for 6 h). Apoptosis was quantified by Hoechst staining. Remarkably, like c-FLIP, 30 ,31 ectopic expression of TRAIL-R4 induced cross-resistance to some chemotherapeutic drugs in vitro and in vivo. How TRAIL-R4 impairs chemotherapy-induced apoptosis remains to be determined. Some reports point to the observation that forced aggregation of some death receptors of the TNF family including Fas, or downstream effectors like Bid, may contribute to genotoxic drug-induced apoptosis in a ligand-independent manner. [31] [32] [33] Combined expression of TRAIL-R4 and c-FLIP may, therefore, not only impair TRAIL-induced cell death after chemotherapy, but may also alter chemotherapy itself. In line with this hypothesis, it has been demonstrated that c-FLIP and TRAIL-R4 are overexpressed in a growing number of primary tumors and that their expression levels has recently been defined as a poor prognostic marker in colorectal 34 and prostate cancer patients. 35 Altogether our results clearly demonstrate that TRAIL-R4 is a negative regulator of TRAIL whose inhibitory function can be overcome using chemotherapy to restore TRAIL-induced cell death. However, we also demonstrate that TRAIL-R4 cooperates with c-FLIP to inhibit TRAIL-induced apoptosis after chemotherapy. Their ability to cooperate and to efficiently inhibit TRAIL-induced apoptosis needs to be taken into consideration both in vitro and in future clinical trials to assess the efficacy of combinatorial treatments associating recombinant TRAIL with chemotherapy. It is anticipated that patients expressing both TRAIL-R4 and c-FLIP may respond better to alternative therapeutic approaches, including 
Materials and Methods
Ligand production and antibodies. Flag-tagged recombinant soluble human TRAIL, his-tagged TRAIL and FasL were produced and used as described previously. 36 Anti-Flag (M2) and staurosporin were from Sigma-Aldrich (Lyon, France). For western blot analysis, anti-TRAIL-R1, anti-TRAIL-R2, anti-TRAIL-R3 and anti-TRAIL-R4 antibodies were purchased from Chemicon (Millipore, Molsheim, France), anti-FADD was obtained from Transduction Laboratories (BD biosciences, Le Pont de Claix, France), anti-caspase-8 and anti-caspase-10 were from Medical & Biological Laboratories (Clinisciences, Montrouge, France). Antibodies against active cleaved fragment of caspase-3, and PARP were from Cell Signaling (Millipore), anti-GFP, Bcl-2, cytochrome c, Bax (N-20) and HSC-70 were from Santa Cruz Biotechnology (Tebu-bio, Le Perray en Yvelines, France) and anti-caspase-9 was from Upstate (Millipore). Anti-Bid, anti-Bcl-xL and anti-FLIP (NF6) antibodies were purchased from BD Pharmingen, Transduction Lab (BD Biosciences), Calbiochem (VWR, Fontenay-sous-Bois, France) and Alexis (Coger, Paris, France), respectively. Anti-CoxII, anti-Smac/DIABLO and anti-Omi/HtrA2 were from Molecular probes (Invitrogen, Cergy Pontoise, France), Proscience (Coger, Paris, France) and R&D systems (Lille, France), respectively. For flow cytometry experiments, the anti-TRAIL-R1, anti-TRAIL-R2, anti-TRAIL-R3 and anti-TRAIL-R4 (clones wB-K32, B-L27, wB-B44 and wB-P30 respectively), were kindly provided by Diaclone (Besançon, France). The secondary antibody was an Alexa-488 coupledgoat anti-mouse from Molecular Probes (Invitrogen). The pan-caspase inhibitor (z-VAD-fmk) and caspase-9 inhibitor (z-LEHD-fmk) were purchased from Alexis.
Cell culture. The HeLa (human cervix carcinoma) and SW480 (human colon adenocarcinoma) cell lines were cultured with high-glucose Dulbecco's modified Eagle's medium medium (Lonza, Levallois-Perret, France) supplemented with 10% fetal bovine serum (Lonza) and penicillin/streptomycin (100 mg/ml of each). The Jurkat (human T lymphoma) cells, VAL (human B lymphoma) and HCT116 human colon adenocarcinoma cell lines were cultured in RPMI 1640 medium (Lonza) containing 10% fetal bovine serum and penicillin/streptomycin. All these cell lines were grown in 5% CO 2 at 371C. HCT116 Bax þ /À or BaxÀ/À are kind gifts of Dr. Bert Vogelstein (Johns Hopkins University School of Medicine, Baltimore, MD, USA).
Retrovirus production and cell transduction. The retroviral vector pMSCV-puro for TRAIL-R4 expression and generation of viruses has been previously described. 37 Cells were transduced for 16 h with viral supernatants containing polybrene (8 mg/ml), washed in PBS, and cultured in complete medium containing puromycin (2.5 mg/ml). EGFP, FLIP L and Bcl-2 were cloned into pBabe-Blasticidin. Transduced cells were then selected with blasticidin (2.5 mg/ml). pMIG-Bcl-xL expression vector 38 was purchased from Addgene (plasmid 8790, Cambridge, MA, USA). pMIG-FLIP L was obtained as previously described.
14 After transduction, cells were sorted using a cell sorter Coulter Epics Elite ESP (Beckman-Coulter-France, Villepinte, France).
Treatments with chemotherapy and TRAIL. For sequential treatments, cells were treated for 3 h with CDDP (20 mM) or VP16 (10 mM) in serum-free medium and then washed. Cells were cultured for 48 h in complete medium before being treated for 6 h with His-TRAIL (500 ng/ml). 5FU was added in complete medium 72 h before TRAIL treatments and the Hoechst analysis.
Hoechst analysis. Apoptosis was assessed by Hoechst staining and determination of the percentage of condensed and fragmented nuclei from at least 300 cells per conditions. Experiments were repeated at least three times.
Bcl-2 and TRAIL-R4 gene silencing by siRNA. TRAIL-R4 siRNA #1 (5 0 -UCCUUAAGUUCGUCGUCUU-3 0 ), TRAIL-R4 siRNA #2 (5 0 -UCACUACCUUAU CAUCAUA-3 0 ) and TRAIL-R4 siRNA #3 (5 0 -GGGUGUGGAUUACACCAUU-3 0 ) were purchased from Eurogentec (Angers, France). Bcl-2 siRNA was purchased from Invitrogen. Cells were transfected with a scramble, Bcl-2 or TRAIL-R4 targeting siRNAs using Amaxa cell line nucleofector kit V (Lonza) with transfection program N016. 48 h after transfection, Bcl-2 and TRAIL-R4 expression were monitored either by western blotting or by flow cytometry, and sensitivity to TRAIL was assessed by Hoechst.
Bax activation by flow cytometry analysis. Cells, treated or untreated with His-TRAIL and/or chemotherapy were fixed with 4% PFA, permeabilized (PBS, BSA 1% and saponin 0.1%) for 10 min at room temperature and stained with an anti-Bax antibody which recognizes the active N-terminal form of Bax (clone 6A7, Tebu-bio). In all, 10 000 events were analyzed using a LSR2 flow cytometer (BD Biosciences).
Digitonin permeabilization. After treatment, cells were washed in PBS and lysed in buffer containing 75 mM KCl, 1 mM NaH 2 PO 4 , 8 mM Na 2 HPO 4 and 250 mM sucrose containing 400 mg/ml digitonin. Cells were kept on ice to obtain 90-95% of . After randomization (day 0), mice were either injected with PBS (white squares), His-TRAIL alone at 8 mg/kg (gray squares), CDDP at 4 mg/kg (black squares) or sequentially with CDDP and 2 days later with His-TRAIL 8 mg/kg (white circle). Mice were subjected to two treatments spaced within 2 days. Tumors were measured every 2 days using a caliper. The combination was found statistically different from single treatments (***Po0.001) at days 14, 16, 18 and 20 as analyzed by ANOVA, two-sided. These results represent mean tumor volume in arbitrary units ± S.D. of 9 to 10 mice per group from three independent experiments trypan blue-permeabilized cells. After 5 min at 16 000 Â g, supernatants were collected as the cytosolic fraction. Pellets were then lysed in buffer containing 1% Triton-X100. After centrifugation for 20 min at 16 000 Â g, supernatants were collected.
Immunoprecipitations. For DISC analysis, 10 8 cells in 1 ml of medium were stimulated with 5 mg Flag-TRAIL cross-linked with 10 mg of M2 antibody for the indicated times at 371C. Cells were then washed with cold phosphate saline buffer, lysed in 1 ml of lysis buffer containing 1% NP40, 20 mM Tris-HCl pH 7.5, 150 mM NaCl and 10% glycerol. Lysates were pre-cleared with Sepharose 6B (SigmaAldrich), and immunoprecipitated overnight at 4 1C with G-protein Sepharose beads (Amersham Biosciences, Les Ullis, France). Beads were then washed four times with the respective detergent, and immunoprecipitates were eluted in lysis buffer (Tris-HCl 63 mM, SDS 2%, phenol red 0.03%, glycerol 10% and DTT 100 mM of pH 6.8), boiled for 5 min and processed for immunobloting.
Western blotting. Immunoprecipitates or cell lysates were resolved by SDS-PAGE and transferred to nitrocellulose membranes. Nonspecific binding sites were blocked by incubation in PBS containing 0.05% of Tween 20 and 5% of milk powder. Immunoblots were then incubated with specific primary antibody followed by HRP-conjugated secondary antibody and were developed by the enhanced chemiluminescence method according to the manufacturer's protocol (Pierce, Rockford, IL, USA). 
